Master the Evolving Hatch-Waxman Landscape: Gain Strategies to Secure Your Competitive Edge and Protect Your Portfolio
This October in Chicago, leading pharmaceutical patent litigators from brand-name and generic drug companies will convene to explore the latest developments in Hatch-Waxman litigation. With significant patent losses and evolving regulations shaping the industry, this forum is more essential than ever, offering critical insights and unparalleled networking opportunities.
Featuring Key Topics
Spotlight on Chevron Overturned in Loper V. Raimondo
Post-Cellect Strategy Session on new Paragraph IV OTDP, PTA concerns
ยง112 Think Tank
Drill down on the Use of Clinical Trials as Prior Art
Focus on Patent Rights and Supply Chain Dynamics
Fireside Chat Future FDA Activity Affecting Small Molecules
Who Should Attend
Patent attorneys and litigators (in-house & law firms) who represent:
- Brand name pharmaceutical companies
- Generic pharmaceutical companies
- Biopharmaceutical companies
Accreditation
Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as non-transitional for the purposes of CLE accreditation.
Learn moreSponsor Opportunities
With conferences in the United States, Europe, Asia Pacific, and Latin America, the C5 Group of Companies: American Conference Institute, the Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.
For more information please contact:
Aaron Goldstein
Senior Business Development Manager
Email: [email protected]
